2021 pROGRESS rEPORT eXECUTIVE SUMMARY

 

 

 

AMR Industry Alliance 2021 Progress Report 

Combatting AMR during COVID-19 

Despite the ongoing challenges presented by the pandemic, the AMR Industry Alliance’s 2021 Progress Report captures efforts made by the life sciences industry to fight AMR across several domains: research and science, access, appropriate use, and manufacturing. The third iteration of this biannual report captures progress made by Alliance members between July 2019 and March 2021. Ahead of the release of the full report, the AMR Industry Alliance is happy to provide a preview of high-level findings by way of the Executive Summary. Below, please find some of the most salient takeaways from the report.

  • AMRIA members continue to engage in research and development (R&D), investing US$1.8-1.9 billion in AMR-relevant R&D annually in FY2019 and FY2020. However, this investment remains fragile, with 32% of members expecting to decrease investment if market conditions do not improve.
  • Although the R&D investment of surveyed AMRIA members is notable, AMRIA membership is not currently representative of the entire R&D pipeline of industry contributions to AMR. This indicates an opportunity for attracting new members to the Alliance to support a fuller representation of the entirety of the industry R&D pipeline.
  • The majority of surveyed companies (81%) were active in supporting access to AMR-relevant products and/or technologies, during the survey reporting timeframe. Companies are also taking action to address substandard and falsified medicines.
  • Appropriate use is a key strategic pillar for most Alliance companies. Overall, 92% of surveyed R&D pharmaceutical companies, 89% of surveyed generics companies and 80% of surveyed diagnostics companies have implemented appropriate use and stewardship activities. This percentage was lower (33%) for biotech/small-and medium-sized entities (SMEs). While the reasons for this merit further research, some biotech/SMEs may not yet have products in late-stage development or on the market and may thus be less engaged with appropriate use and stewardship activities.
  • Alliance members have an opportunity to strengthen their work on surveillance and data transparency. During the survey timeframe, slightly more than half (51%) of members reported collecting and/or sharing surveillance data to generate evidence to support appropriate use and stewardship.
  • Alliance members are making significant contributions to the appropriate manufacturing of antibiotics. The majority (76%) of antibiotic manufacturing sites owned by Alliance members and assessed against the Common Antibiotic Manufacturing Framework (CAMF) fully met all framework requirements, and almost all (98%) met requirements either fully or partially. Moreover, most products manufactured at Alliance members’ sites (88%) have been assessed against Predicted No-Effect Concentration (PNEC) targets, and most of the assessed products (87%) meet these targets 
  • Through cross-sectoral and collaborative engagement, Alliance members can continue to support efforts to accelerate adoption of the manufacturing framework across the supply chain and spur continued contributions toward meeting standards, especially for newer and incoming members who will need time to implement actions.

 

The report is based on independent, quality assured research conducted by RAND Europe and funded by the AMR Industry Alliance.

AMR INDUSTRY ALLIANCE MEMBERS

The AMR Industry Alliance was established in 2017. Representing a diverse coalition of biotechnology, diagnostics, generics, and large research-based biopharmaceutical companies and associations, the Alliance drives progress on AMR by the life sciences industry. With approximately 100 companies and trade associations from 20 countries, it covers nearly one third of the global antibiotic supply and the majority of novel products.

For the full list of members, please follow this link.